ALVO — Alvotech
—
Nasdaq ·
Health Care ·
Biotechnology ·
CIK 1898416 ·
Last close
$5.78
Market Cap
$2.06B
52W High
$9.05
52W Low
$2.94
ADV30
1,162,560
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | — | -66,821,000 | 1,587,468,000 | 142,750,000 | — |
| Mar 2026 | 105,865,000 | 59,778,000 | 9,674,000 | 1,030,000 | 1,421,168,000 | 63,832,000 | 1,703,480,000 |
| Dec 2025 | 166,573,000 | 105,293,000 | 48,255,000 | -108,547,000 | 1,487,099,000 | 172,359,000 | 1,771,586,000 |
| Sep 2025 | 113,744,000 | 78,738,000 | 1,313,000 | -5,252,000 | 1,409,178,000 | 42,848,000 | 1,585,941,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-123,175,000
Investing CF
$-130,015,000
Financing CF
$275,704,000
CapEx
$-118,954,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.35
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,408,760,000
Inventory
$228,017,000
Receivables
$133,054,000
ST Investments
—
EBIT TTM
$186,051,000
Pretax Income TTM
$43,913,000
Interest Exp TTM
$142,138,000
Analysts
4
Yahoo Snapshot (yfinance, live)
Total Revenue
$494,608,000
EBITDA
$75,733,000
Free Cash Flow
$-123,130,128
Enterprise Value
$3,196,597,248
Total Cash
$142,750,000
Total Debt
$1,451,784,960
Shares Out
356,817,038
Trailing EPS
$-0.62
Book Value
$-0.54
ROE
—
ROA
2.2%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 586,321,000 | 78,207,000 | 27,919,000 | 1,487,099,000 | 1,771,586,000 | -284,487,000 | -50,197,000 |
| Dec 2024 | 489,682,000 | 69,644,000 | -231,864,000 | 1,221,400,000 | 1,634,171,000 | -412,771,000 | -236,843,000 |
| Dec 2023 | 91,434,000 | -354,860,000 | -551,731,000 | 950,090,000 | 1,882,583,000 | -932,493,000 | -312,185,000 |
| Dec 2022 | 83,029,000 | -346,442,000 | -513,580,000 | 828,443,000 | 1,392,859,000 | -564,416,000 | -312,389,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$0.23
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| VCEL | Vericel Corp | $2.05B | $40.10 | — |
| NVAX | NOVAVAX INC | $2.10B | $12.75 | — |
| MEOBF | MESOBLAST LTD | $1.99B | $1.53 | — |
| VIR | Vir Biotechnology, Inc. | $1.98B | $11.70 | — |
| BCRX | BIOCRYST PHARMACEUTICALS INC | $2.18B | $8.55 | — |
News headlines (Yahoo Finance, 1h cache)
LOTTE Biologics and Alvotech announce US-based manufacturing agreement to increase global supply
2026-10-08 11:17 · Yahoo
Alvotech (ALVO) Could Be 14% Undervalued On Manufacturing Capacity Updates
2026-10-08 11:15 · Yahoo
Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supply
2026-10-06 20:37 · Yahoo
Alvotech Soars 13% on FDA Nod That “Effectively Doubles” US Humira Biosimilar Capacity
2026-10-05 19:14 · Yahoo
Alvotech stock surges after FDA manufacturing approval
2026-10-05 15:21 · Yahoo
FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®
2026-10-05 08:00 · Yahoo
Why This Biotech Stock Just Got a Rare Double Upgrade
2026-09-16 20:25 · Yahoo
ALVO Stock Jumps On Double Upgrade — Why Barclays Sees A 59% Upside
2026-09-16 18:33 · Yahoo
Alvotech Shares Rise 5.6% After Barclays Upgrades Rating and Doubles Price Target
2026-09-16 10:53 · Yahoo
Alvotech announces FDA acceptance for review of Biologics License Application for AVT80, expanding proposed biosimilar program for Entyvio® to subcutaneous presentations
2026-08-31 08:30 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.